drugset

drugset / Trial / NCT05930561

4D-150 in Patients With Diabetic Macular Edema

NCT05930561 ↗

Phase 2 Active not recruiting 72 enrolled 4D Molecular Therapeutics

Non-randomizedParallel-groupDouble-blindTreatment

Summary

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Timeline

Start: 2023-08-09
Primary completion: 2029-02-28
Completion: 2029-02-28

Publications

Calton MA, Croze RH, Burns C, Beliakoff G, Vazin T, Szymanski P, Schmitt C, Klein A, Leong M, Quezada M, Holt J, Bolender G, Barglow K, Khoday D, Mason T, Delaria K, Hassanipour M, Kotterman M, Khanani AM, Schaffer D, Francis P, Kirn D. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):1. doi: 10.1167/iovs.65.14.1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	4D-150	Gene therapy (AAV / viral vector)	—	Intravitreal
Comparator	Aflibercept	Protein / enzyme biologic	—	Intravitreal

Indications